This trial is comparing the efficacy and safety of bb2121 versus standard regimens in subjects with relapsed and refractory multiple myeloma.
1 Primary · 18 Secondary · Reporting Duration: Minimum 5 years after bb2121 infusion
Experimental Treatment
381 Total Participants · 2 Treatment Groups
Primary Treatment: bb2121 · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: